Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 262

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 262
---
 initiatives and those expenses for the fiscal year ended March 31, 2024 include expenses related to lease termination agreement to consolidate the offices for the purpose of maximizing organizational effectiveness.

Rebates and Returns

Takeda has recognized a provision related mainly to sales rebates and returns for products and merchandises. The balances stated in the summary table above include provisions of JPY 253,832 241,704S ales rebates and sales returns reserves are reviewed and updated monthly or when there is a significant change in its amount.

Other

Other provisions are primarily related to post-trial access costs for the terminated program (Note 5), asset retirement obligations, contract termination fees and onerous contracts.

24. Other Liabilities

                        JPY (millions)                            
                        As of March 31                            
                        2024                                      
 ──────────────────────────────────────────────────────────────────
  Accrued expenses      ¥                   627,659      605,697  
  Deferred income                            30,015       38,213  
  Other                                      42,439       34,916  
  Total                 ¥                   700,112      678,826  
  Non-current           ¥                    80,938       82,542  
  Current               ¥                   619,174      596,283  

Accrued expenses include accrued employee benefit expenses of JPY 283,359 291,957

Deferred income includes contract liabilities related to out-licensing agreements, product procurement and supply agreements, and government grants for the purchase of property, plant and equipment. The grants received were JPY 14,211 12,001

25. Trade and Other Payables

                      JPY (millions)                                      
                      As of March 31                                      
                      2024                             2025               
 ──────────────────────────────────────────────────────────────────────────
  Trade payables      ¥                   319,955      ¥         308,450  
  Other payables                          227,566                167,091  
  Total               ¥                   547,521      ¥         475,541  

F-54

26. Equity and Other Equity Items

                                                         Thousands of Shares                                                  
                                                         For the Year Ended March 31                                          
                                                         2024                                            2025                 
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Authorized shares as of the beginning of the year                                       3,500